Phase 1/2 oncology biotech developing RAS pathway inhibitors.
Industry: Health Care
First Day Return: +70.0%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 01/17/2020 |
Offer Price | $17.00 |
Price Range $16.00 - $17.00 | |
Offer Shares (mm) | 14.0 |
Deal Size ($mm) | $238 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 02/12/2020 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $238 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | Redwood City, CA, United States |
Founded | 2015 |
Employees at IPO | 90 |
Website www.revmed.com |